The role of antisecretory drugs in the treatment of Helicobacter pylori infection
|
|
- Jesse Fletcher
- 6 years ago
- Views:
Transcription
1 Aliment Pharmacol Ther 1997; 11 (Suppl. 1): The role of antisecretory drugs in the treatment of Helicobacter pylori infection W. L. PETERSON Department of Internal Medicine, University of Texas Southwestern Medical School and Medical Service, Dallas Department of Veterans Affairs Medical Center, Dallas, USA SUMMARY The efficacy of antibiotics against Helicobacter pylori is enhanced by the co-administration of antisecretory drugs. While proton pump inhibitors appear to have some direct effect on H. pylori and extreme hypochlorhydria has a deleterious effect on the organism, the most likely mechanism by which antisecretory drugs as a class provide this effect is by improving the efficacy of the antibiotics themselves. Although proton pump inhibitors are the most widely used antisecretory agents, H receptor antagonists also enhance antibiotic effects. INTRODUCTION Antisecretory drugs have assumed a role in the treatment of Helicobacter pylori infection for several reasons. First, early studies of patients with active peptic ulcers simply added anti-h. pylori regimens such as bismuth triple therapy to standard antisecretory therapy. Only later was it recognized that H. pylori therapy alone could heal ulcers without concomitant antisecretory therapy., Such studies suggest that although addition of an antisecretory agent reduces ulcer pain more rapidly than with H. pylori therapy alone, the rates of ulcer healing are comparable., Second, it was recognized early on, and has since been confirmed by many studies, that antibiotics alone yield inadequate cure rates for H. pylori infection. Even a combination of three antibiotics (clarithromycin, amoxicillin, and metronidazole) eradicates H. pylori only about 60% of the time. Because the efficacy of some antibiotics are diminished at low ph, antisecretory agents were added. Third, it has been noted that proton pump Correspondence to: Professor W. L. Peterson, Dallas VAMC (111B1), 4500 S. Lancaster Road, Dallas, TX 75216, USA inhibitors have direct in vitro inhibitory effects against H. pylori. H. PYLORI CURE RATES WITH AND WITHOUT ANTISECRETORY DRUGS There are few studies in which direct comparisons have been made between antibiotics alone and antibiotics plus an antisecretory drug. Therefore, most of the cure rates noted in this section represent amalgamated data from the literature and from review articles. Inherent in this approach is a substantial lack of precision due to the wide difference in study design and analysis. On the other hand, precise values are less important for this exercise than establishing the concept that addition of an antisecretory drug enhances the effect of antibiotics in curing H. pylori infection. The antibiotics best studied as single agents are amoxicillin and clarithromycin. As shown in Table 1, cure rates with these antibiotics alone are approximately 20%, and 40%, respectively. The nitroimidazoles (metronidazole, tinidazole) alone have virtually no effect as monotherapy owing to the rapid development of resistance by H. pylori. Addition of standard doses of ranitidine to amoxicillin or clarithromycin results in cure rates about 15% higher than with the antibiotic alone, 1997 Blackwell Science Ltd 21
2 22 W. L. PETERSON Table 1. Approximate cure rates of H. pylori infection with antibiotic regimen alone or combined with an H receptor antagonist (H RA) or proton pump inhibitor (PPI) Cure rate (%) Antibiotic(s) Alone H RA PPI Amoxicillin Clarithromycin Amoxicillin nitromidazole Clarithromycin nitromidazole Bismuth triple therapy although published data are limited (pers comm, Glaxo Wellcome). Addition of higher doses of ranitidine or, better studied, omeprazole to amoxicillin or clarithromycin give cure rates of approximately 60%,, and 70%,,,, respectively. Dual antibiotic therapy has most frequently consisted of amoxicillin or clarithromycin plus a nitroimidazole, with eradication rates of approximately 60%.,, Concomitant use of an H receptor antagonist results in cure rates 10 20% higher (Table 1)., Even better results have been found with the addition of a proton pump inhibitor, giving eradication rates of 80% with amoxicillin plus a nitroimidazole and 90% with clarithromycin plus a nitroimidazole.,, Triple therapy with bismuth, metronidazole, and amoxicillin or tetracycline without antisecretory therapy results in cure rates of approximately 80%, which increases to 90% and 95% with the addition of an H receptor antagonist or proton pump inhibitor, respectively., Two studies have recently been published directly comparing bismuth triple therapy alone to bismuth triple therapy with omeprazole., Using an intention to treat analysis, the eradication rate rose from 83.3% with bismuth triple therapy alone to 98.1% with triple therapy plus omeprazole in one and from 80% to 86% in the other. The reasons for the discrepant results in these two studies are not known. Recognizing the limitations of the above data, it nevertheless appears clear that addition of an antisecretory agent enhances the H. pylori eradication rates of whichever antibiotic regimen it is added to. Less clear are the mechanisms by which antisecretory agents accomplish these results. POSSIBLE MECHANISMS BY WHICH ANTISECRETORY DRUGS ENHANCE THE EFFECTS OF ANTIBIOTICS The antisecretory drug has a direct effect on H. pylori The antimicrobial effects of antisecretory agents against H. pylori have been studied in vitro and in vivo (Table 2). In vitro. H receptor antagonists have no effect on survival of H. pylori in standard culture media. Omeprazole, on the other hand, when added to culture media causes a substantial decrease in survival at ph levels 6.0 and below, but not at ph 7.0. For example, the addition of 100 µg ml of omeprazole at ph 4.0 resulted in a 5 6 log reduction of survival. A similar, but less pronounced, decrease in survival was noted for Escherichia coli, Proteus mirabilis, and Staphylococcus typhimurium (Table 3). In vivo, omeprazole is converted in the acidic milieu of the parietal cell to its active form, a sulphenamide. This would theoretically also occur in the gastric lumen at acidic ph levels but not at ph 7. Such a phenomenon might explain why omeprazole was effective at lower ph levels but had no inhibitory effect at ph 7.0. Therefore, survival studies were repeated using omeprazole that had been preactivated at ph 5.0 for 20 min. With pre-activation, omeprazole now reduced survival at ph 7 as well. Thus, when omeprazole is in an acidic milieu or is pre-activated with acid, it effectively inhibits survival of H. pylori and other enteric bacteria in vitro. Table 2. Effects of antisecretory therapy alone on H. pylori Agent In vitro In vivo H receptor antagonist No effect No effect Omeprazole Decreased Suppression survival Table 3. Effect of omeprazole (100 µg ml) on survival of H. pylori and other enteric pathogens at ph 4.0 Bacterium H. pylori 6.07 Escherichia coli 3.88 Proteus mirabilis 2.58 Staphyloccocus typhimurium 3.30 Log decrease survival after 60 min
3 ANTISECRETORY AGENTS AND TREATMENT OF H. PYLORI INFECTION 23 In vivo. In vivo results of H receptor antagonists and omeprazole are shown in Table 2. Not surprisingly, H receptor antagonists have no effect. Administration of omeprazole alone results in the inability to detect H. pylori immediately after therapy in up to 50% of subjects, but when diagnostic tests are conducted at least 4 weeks after cessation of therapy, eradication is confirmed 5% of the time.,, The phenomenon of temporary inability to detect the presence of H. pylori is termed suppression and may simply reflect a decrease in the number of organisms below the limits of detection of standard diagnostic tests. One mechanism by which omeprazole may suppress H. pylori is, as shown from in vitro studies, by a direct antimicrobial effect of the compound. However, two observations cast doubt on this mechanism. First, omeprazole is manufactured as an enteric-coated drug and would not be found in an acidic stomach. Second, in an alkaline environment, such as would be present after several days of therapy with omeprazole, the drug could be released from its enteric coating but might not be acid-activated to its active form, the sulphenamide. To resolve this issue, studies are needed to determine if omeprazole and or its sulphenamide can be recovered from gastric juice. Another mechanism by which omeprazole might effect survival of H. pylori is through hypochlorhydria. Antisecretory drug-induced hypochlorhydria is deleterious to survival of H. pylori H. pylori survives with difficulty at very high ph. The formation of ammonia from urease-induced hydrolysis of urea, which allows the organism to survive at low ph, may serve to suffocate the organism at high ph., This might also be the reason why organisms tend to migrate from the more alkaline antrum to the less alkaline corpus during antisecretory therapy, although not all investigators believe this phenomenon occurs. It is further possible that high ph levels promote the overgrowth of other bacteria which might compete with H. pylori for survival or that secreted immunoglobulin is degraded to a lesser degree at lower levels of acidity. As proton pump inhibitors produce ph levels higher than with H receptor antagonists, this might explain why the former suppress H. pylori in vivo while the latter do not. It might also explain why the eradication rates shown in Table 1 are uniformly higher when antibiotics are combined with proton pump inhibitors than when they are combined with H receptor antagonists. Finally, this might explain why several studies using a fixed dose of amoxicillin combined with increasing doses of omeprazole have found higher eradication rates with higher doses of omeprazole. On the other hand, there are several lines of evidence against the hypothesis that hypochlorhydria per se is the most important (or only) mechanism by which antisecretory drugs enhance eradication rates of H. pylori. First, not all investigators have found that there is a dose response of omeprazole when combined with amoxicillin., Second, the data shown in Table 1 are not from direct comparative studies. A recent study has directly compared amoxicillin plus either omeprazole or ranitidine. Although gastric acidity was lower with omeprazole, cure rates of H. pylori did not differ. Furthermore, a meta-analysis of parallel group trials comparing H receptor antagonists and omeprazole found similar eradication results (76.5% and 78.6%, respectively). Thus, there is reasonable doubt that proton pump inhibitors are more effective than H receptor antagonists in combination with antibiotics or that greater degrees of acid suppression provide higher rates of eradication. The antisecretory drug has an effect on the antibotics A third means by which antisecretory drugs might enhance the efficacy of antibiotics in eradicating H. pylori is by affecting the antibiotics themselves. This could occur in several ways. There is evidence that antibiotic activity (i.e. minimum inhibitory concentrations) and stability are greater at higher ph, especially with amoxicillin. In one study, the activity of clarithromycin against H. pylori decreased almost 16-fold when the ph of the medium was changed from 7.2 to 5.5. Another possibility is that antisecretory drugs alter the pharmacokinetics or tissue distribution of antibiotics. For example, omeprazole increases blood and gastric tissue concentrations of clarithromycin and gastric juice concentrations of amoxicillin. Increased levels of antibiotics in gastric juice and tissue are likely a result of less tissue washout of antibiotics from the secretion of gastric juice and decreased gastric juice volume. CONCLUSION It is possible to cure H. pylori infection with regimens that do not include anti-secretory drugs. However, the addition of anti-secretory drugs enhances the efficacy of almost all such regimens and, in patients with active
4 24 W. L. PETERSON peptic ulcers, speeds the relief of symptoms. The mechanisms by which anti-secretory drugs enhance antimicrobial efficacy have not been clearly determined but are probably multiple. REFERENCES 1 Graham DY, Lew GM, Evans DG, Evans DJ, Klein PD. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. Ann Intern Med. 1991; 115: Hosking SW, Ling TKW, Chung SCS, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet. 1994; 343: Lam SK, Ching CK, Lai KC, et al. Does treament of Helicobacter pylori (Hp) with antibiotics alone heal duodenal ulcer (DU)? A randomised double-blind placebo controlled study. Gastroenterology 1996; 110: A169 (Abstract). 4 Penston JG. Review article: clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease. Aliment Pharmacol Ther 1996; 10: Unge P, Gad A, Gnarpe H, Olsson J. Does omeprazole improve antimicrobial therapy directed towards Campylobacter pylori in patients with antral gastritis? Scand J Gastroenterol 1989; 24: McGowan CC, Cover TL, Blaser MJ. The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism. Gastroenterology. 1994; 107: Chiba N, Rao B, Rademaker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol. 1992; 87: Dixon JS. Helicobacter pylori eradication: unravelling the facts. Scand J Gastroenterol. 1995; 30 (Suppl. 212): Chiba N, Wilkinson J, Hunt RH. Omeprazole and clarithromycin in Helicobacter pylori eradication: a meta-analysis. Gastroenterology 1996; 110: A80 (Abstract). 10 Goodwin CS, Marshall BJ, Blincow ED, et al. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol 1988; 41: Pentson JG. Review article: Helicobacter pylori eradication understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994; 8: van der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996; 1: Axon ATR, Moayyedi P. Eradication of Helicobacter pylori: omeprazole in combination with antibiotics. Scand J Gastroenterol. 1996; 31 (Suppl. 215): Bazzoli F, Zagari RM, Fossi S, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori: a randomized, double-blind, controlled study. Gastroenterology 1996; 110: A61 (Abstract). 15 Yousfi MM, El-Zimaity HMT, Cole RA, Genta RM, Graham DY. Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli s triple therapy). Aliment Pharmcol Ther 1996; 10: Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one week triple therapies combining omeprazole with two antimicrobials the MACH 1 study. Helicobacter 1996; 1: Yousfi MM, El-Zimaity HM, Al-Assi MT, et al. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9: deboer W, Driessen W, Jansz A, Tytgat G. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995; 345: Goodwin CS, Blake P, Blincow E. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrob Chemother 1986; 17: Graham DY, Klein PD, Opekun AR, et al. In vivo susceptibility of Campylobacter pylori. Am J Gastroenterol 1989; 84: Weil J, Bell GD, Powell K, et al. Omeprazole and Helicobacter pylori: temporary suppresion rather than true eradication. Aliment Pharmacol Ther 1991; 5: Daw MA, Deegan P, Leen E, O Morain C. Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis. Aliment Pharmacol Ther 1991; 5: Clyne M, Labigne A, Drumm B. Helicobacter pylori requires an acidic environment to survive in the presence of urea. Infect Immun 1995; 63: Neithercut WD, Greig MA, Hossack M, McColl KEL. Suicidal destruction of Helicobacter pylori: metabolic consequence of intracellular accumulation of ammonia. J Clin Pathol 1991; 44: Logan RPH, Walker MM, Misiewicz JJ, et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995; 36: Graham DY, Genta R, Evans DG, et al. H. pylori does not migrate from the antrum to the corpus in response to omeprazole. Am J Gastroenterol. 1996; 91: Bayerdorffer E, Miehlke S, Mannes GA, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori in patients with duodenal ulcers. Gastroenterology 1995; 108: van der Hulst RWM, Weel JFL, Verheul SB, et al. Treatment of Helicobacter pylori infection with low- or high-dose omeprazole combined with amoxicillin and the effect of retreatment: a prospective, randomized, double-blind study. Aliment Pharmacol Ther 1996; 10: Malaty H, El-Zimaity HMT, Genta RM, Cole RA, Graham DY. High-dose proton pump inhibitor plus amoxicillin for the treatment or retreatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1996; 10: Adamek RJ, Labenz J, Opferkuch W, et al. Ranitidine amoxicillin vs omeprazole amoxicillin for cure of H. pyloripositive gastric ulcer: Role of acid suppression. Gastroenterology. 1995; 108: A44 (Abstract). 31 Holtmann G, Layer P, Goebell H. Proton pump inhibitors or H - receptor antagonists for H. pylori eradication. Meta-analysis of
5 ANTISECRETORY AGENTS AND TREATMENT OF H. PYLORI INFECTION 25 parallel group studies. Gastroenterology. 1996; 110: A136 (Abstract) 32 Cederbrant G, Kahlmeyer G, Schalen C, Kamma C. Additive effect of clarithromycin combined with 14-OH clarithromycin, erythromycin, amoxicillin, metronidazole, or omeprazole against H. pylori. J Antimicrob Chemother 1994; 34: Hunt RH. Hp and ph: implications for the eradication of Helicobacter pylori. Scand J Gastroenterol 1993; 28 (Suppl. 196): Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol 1994; 29 Suppl. 201: Gustavson LE, Kaiser JF, Edmonds AL, et al. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995; 39: Goddard AF, Jessa MJ, Barrett DA, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996; 111:
One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers
Aliment Pharmacol Ther 1997; 11: 89 93. One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers J. LABENZ*, J.-P. IDSTRO M, B. TILLENBURG*,
More informationHelicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.
UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published
More informationORIGINAL INVESTIGATION. Effectiveness of Helicobacter pylori Therapies in a Clinical Practice Setting
ORIGINAL INVESTIGATION Effectiveness of Helicobacter pylori Therapies in a Clinical Practice Setting M. Brian Fennerty, MD; David A. Lieberman, MD; Nimish Vakil, MD; Nathan Magaret; Douglas O. Faigel,
More informationHelicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.
UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published
More informationTitle. Author(s)Kato, Mototsugu. Issue Date Doc URL. Type. Note. File Information.
Title Effects of lansoprazole plus amoxycillin on the cure Author(s)Kato, Mototsugu Issue Date 1996-12-25 Doc URL http://hdl.handle.net/2115/32629 Type theses (doctoral) Note 共著者あり 共著者名 :Asaka Masahiro,
More informationThree-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study
Aliment Pharmacol Ther 2001; 15: 843±849. Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study B. C. Y. WONG*, W. H. WANG*, W.M.WONG*,G.K.K.LAU*,F.M.Y.FUNG*,N.N.S.KUNGà,
More informationTreatment of H. pylori Infection: The Reality
YALE JOURNAL OF BIOLOGY AND MEDICINE 71 (1998), pp. 119-124. Copyright 1999. All rights reserved. Treatment of H. pylori Infection: The Reality Nimish Vakil University of Wisconsin Medical School, Milwaukee
More informationYang K. Chen, MD* Prahalad Jajodia, MD Lino DeGuzman, MD Shahid A. Khan, MD Vaman S. Jakribettuu, MD*
Randomized Controlled Trial Comparing Proton Pump Inhibitor- Based Eradication Regimen versus Low-Cost Eradication Regimen for Patients with Helicobacter pylori with Uninvestigated Dyspepsia Yang K. Chen,
More informationOmeprazole enhances efficacy of triple therapy in eradicating Helicobacter pyloni
Gut 1995; 37: 477-481 Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pyloni 477 Centre for Digestive Diseases, Five Dock, NSW, Australia T J Borody P Andrews G Fracchia S Brandl
More informationArab Journal of Gastroenterology
Arab Journal of Gastroenterology 14 (2013) 1 5 Contents lists available at SciVerse ScienceDirect Arab Journal of Gastroenterology journal homepage: www.elsevier.com/locate/ajg Original Article Penbactam
More informationRapid increase in the prevalence of metronidazole resistant Helicobacter pylori in the Netherlands.
Chapter 2 Rapid increase in the prevalence of metronidazole resistant Helicobacter pylori in the Netherlands. E.J.van der Wouden 1, A.A.van Zwet 2, J.C.Thijs 1, G.D.C.Vosmaer 3, J.A.J.Oom 4, A.de Jong
More informationAntibiotic resistance is now often understood at the VIEWPOINTS IN DIGESTIVE DISEASES
GASTROENTEROLOGY 1998;115:1272 1277 VIEWPOINTS IN DIGESTIVE DISEASES Antibiotic Resistance in Helicobacter pylori: Implications for Therapy DAVID Y. GRAHAM Department of Medicine, Veterans Affairs Medical
More information(Index words: Clarithromycin, compliance, efficacy, tinidazole and omeprazole therapy)
Comparison of one week and two weeks of triple therapy for the eradication of Helicobacter pylori in a Sri Lankan population: a randomised, controlled study HA de Silva 1, J Hewavisenthi 2, A Pathmeswaran
More informationTHE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 93, No. 10, 1998 Copyright 1998 by Am. Coll. of Gastroenterology ISSN /98/$19.
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 93, No. 10, 1998 Copyright 1998 by Am. Coll. of Gastroenterology ISSN 0002-9270/98/$19.00 Published by Elsevier Science Inc. PII S0002-9270(98)00340-2 Cure
More informationHelicobacter pylori eradication in chronic duodenal ulcer disease - a community-based study
Postgrad MedJ 1995; 71: 413-418 The Fellowship of Postgraduate Medicine, 1995 Original articles Northwick Park Hospital, Harrow, Middlesex HA1 3UJ, UK Department of Gastroenterology PS Phull SD Ryder AJ
More informationEradication of Helicobacter pylori: an objective assessment of current therapies
Br J Clin Pharmacol 1997; 43: 223 243 Eradication of Helicobacter pylori: an objective assessment of current therapies J. G. Penston & K. E. L McColl 1 Scunthorpe General Hospital, Scunthorpe and 1 Department
More informationReview article: pharmacology of esomeprazole and comparisons with omeprazole
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 5 9. Review article: pharmacology of esomeprazole and comparisons with omeprazole J. DENT Department of Gastroenterology, Hepatology and General Medicine, Royal
More informationA Heaney, J S A Collins, RGPWatson, R J McFarland, K B Bamford, T C K Tham
186 Royal Victoria Hospital, Belfast, A Heaney J S A Collins Department of Medicine, Queen s University, Belfast, RGPWatson Ulster Hospital, Dundonald, R J McFarland T C K Tham Department of Microbiology
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationHelicobacter pyloni and upper gastrointestinal
314 Helicobacter pyloni and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom Gut 1995; 37: 314-318 R Milne, R P H Logan, D Harwood, J J Misiewicz, D Forman Health Services
More informationTreating H. pylori in 2016
Treating H. pylori in 2016 William D. Chey, MD, FACG Professor of Medicine University of Michigan The Case: A 38 yo Russian man presents with recurrent epigastric pain which occurs after meals and sometimes
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationProton pump inhibitor (proton pump inhibitor)-based triple therapies using clarithromycin in combination SUMMARY INTRODUCTION
Aliment Pharmacol Ther 2003; 18: 799 804. doi: 10.1046/j.1365-2036.2003.01764.x Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter
More informationWhat is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?
What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? Sequential Therapy Versus Standard Triple- Drug Therapy for Helicobacter pylori
More informationHelicobacter pylori: Diagnosis, treatment and risks of untreated infection
Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb
More informationThe long-term management of patients with bleeding duodenal ulcers
Aliment Pharmacol Ther (1997); 11: 505±510. The long-term management of patients with bleeding duodenal ulcers M. E. MCALINDON, J. S. W. TAYLOR & S. D. RYDER Department of Medicine, University Hospital,
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More information헬리코박터파일로리감염에서고용량및다빈도덱스란소프라졸과아모시실린이중치료 : 단일군전향연구
Korean J Gastroenterol Vol. 70 No. 4, 176-180 https://doi.org/10.4166/kjg.2017.70.4.176 pissn 1598-9992 eissn 2233-6869 ORIGINAL ARTICLE 헬리코박터파일로리감염에서고용량및다빈도덱스란소프라졸과아모시실린이중치료 : 단일군전향연구 박혜윤, 강은정, 김동근, 김기주,
More informationHelicobacter Connections. Barry Marshall
Helicobacter Connections Barry Marshall The greatest obstacle to knowledge is not ignorance, it is the illusion of knowledge. Daniel Boorstein - Historian Peptic Ulcers Duodenal Ulcer (DU) Gastric Ulcer
More informationORIGINAL INVESTIGATION. Maintenance Treatment Is Not Necessary After Helicobacter pylori Eradication and Healing of Bleeding Peptic Ulcer
ORIGINAL INVESTIGATION Maintenance Treatment Is Not Necessary After Helicobacter pylori Eradication and Healing of Bleeding Peptic Ulcer A 5-Year Prospective, Randomized, Controlled Study Chen-Chiung Liu,
More informationEMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated
EMILOK Global (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated granules. Properties: Emilok (omeprazole) belongs to the group of proton pump inhibitors, inhibits both
More informationAntibiotic resistance in Helicobacter pylori infection
Antibiotic resistance in Helicobacter pylori infection Francis Megraud haboratoire de Bacteriologie, Hopital Pellegrin, Bordeaux, France Resistance to antibiotics is considered as the primary reason for
More informationMaastricht Ⅴ /Florence
2016 21 10 577 Maastricht Ⅴ /Florence 200001 2015 10 8 9 Maastricht V 1 / 2 3 4 / 5 Maastricht Ⅴ Interpretation of Management of Helicobacter pylori Infection the Maastricht Ⅴ / Florence Consensus Report
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/48400
More informationReview article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 10 15. Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors J. G. HATLEBAKK Department of Medicine, Haukeland Sykehus,
More informationLow-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients
Blackwell Science, LtdOxford, UKJGHJournal of Gastroenterology and Hepatology0815-93192005 Blackwell Publishing Asia Pty Ltd206935940Original ArticleLow-dose rabeprazole-based triple therapywm Wong et
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationPerspectives from Viet Nam
International Symposium I (Management of antibiotics-resistant Helicobacter pylori infection) Perspectives from Viet Nam Vu Van Khien 1,HoDangQuyDung 2, Tran Thanh Binh 2 1 Department of GI Endoscopy,
More informationIntragastric Acidification Reduces the Occurrence of False-Negative Urea Breath Test Results in Patients Taking a Proton Pump Inhibitor
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 96, No. 4, 2001 2001 by Am. Coll. of Gastroenterology ISSN 0002-9270/01/$20.00 Published by Elsevier Science Inc. PII S0002-9270(01)02250-X Intragastric Acidification
More informationPrevpac Pylera Omeclamox-Pak
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.21 Subject: -Pak Page: 1 of 5 Last Review Date: September 20, 2018 -Pak Description (lansoprazole,
More informationPEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School
PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/59359
More informationThe annual incidence of peptic ulcer disease in developed
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2003;1:273 278 Pretreatment Antimicrobial Susceptibility Testing Is Cost Saving in the Eradication of Helicobacter pylori MARCO ROMANO,* RICCARDO MARMO, ANTONIO
More informationThe effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme
Aliment Pharmacol Ther 2000; 14: 719±728. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme P. MOAYYEDI*, R. FELTBOWER,
More informationGilles Jequier. Commercial Director Organobalance, a Novozymes Company
"Latest clinical Evidences showing that a proprietary Lactobacillus reuteri Strain can reduce the Symptoms associated with a Helicobacter pylori Infection" Gilles Jequier Commercial Director Organobalance,
More informationHelicobacter pylori Eradication Therapy Success Regarding Different Treatment Period Based on Clarithromycin or Metronidazole Triple-Therapy Regimens
Helicobacter ISSN 1523-5378 Filipec Blackwell Oxford, HEL 1083-4389 1523-5378 Journal XXX Original H. 2008 pylori Kanizaj compilation The UK Eradication Publishing Article Authors et al. Ltd 2008 Therapy
More informationTreatment for H. pylori Infection. New Challenges With Antimicrobial Resistance
CLINICAL REVIEW Treatment for H. pylori Infection New Challenges With Antimicrobial Resistance Nimish Vakil, MD, FACP, FACG, AGAF, FASGE* and Dino Vaira, MDw Abstract: The treatment of Helicobacter pylori
More informationRole of antimicrobial susceptibility testing on ef cacy of triple therapy in Helicobacter pylori eradication
Aliment Pharmacol Ther 2000; 14: 1639±1643. Role of antimicrobial susceptibility testing on ef cacy of triple therapy in Helicobacter pylori eradication S. TORACCHIO*, L. CELLINI, E.DICAMPLI, G.CAPPELLO*,M.G.MALATESTA*,A.FERRI*,
More informationHelicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.
UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published
More informationOne week triple therapy for Helicobacter pylori:a multicentre comparative study
Gut 1997; 41: 735 739 735 PAPERS Central Middlesex Hospital, London J J Misiewicz A W Harris Rotherham District Hospital K D Bardhan Northwick Park Hospital, Slough S Levi The Meath Hospital, Dublin C
More informationTreatment of Helicobacter pylori in Patients With Duodenal Ulcer Hemorrhage A Long-Term Randomized, Controlled Study
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 95, No. 9, 2000 2000 by Am. Coll. of Gastroenterology ISSN 0002-9270/00/$20.00 Published by Elsevier Science Inc. PII S0002-9270(00)01041-8 Treatment of Helicobacter
More informationThe diagnosis and management of H. pylori infection in Singapore
Singapore Med J 2017; 58(5): 234-240 doi: 10.11622/smedj.2017037 CMEArticle The diagnosis and management of H. pylori infection in Singapore Claire Alexandra Zhen Chew 1, MBChB, Tong Fong Lye 2, MBBS,
More informationThe effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori
Aliment Pharmacol Ther 1999; 13: 667±673. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori A. PILOTTO*, G. LEANDRO, M. FRANCESCHI*, M. RASSUà,
More informationAcid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe
Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs 1 Division of Gastroenterology UC San Diego School of Medicine Clinical presentations of Helicobacter pylori infection
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationHelicobacter pylori Eradication Therapy Research: Ethical Issues and Description of Results
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:1032 1036 PERSPECTIVE Helicobacter pylori Eradication Therapy Research: Ethical Issues and Description of Results DAVID Y. GRAHAM Department of Medicine,
More informationHelicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment
Aliment Pharmacol Ther 2003; 18: 93 100. doi: 10.1046/j.0269-2813.2003.01649.x Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily
More informationThe interactions between Helicobacter pylori, acid, and
GASTROENTEROLOGY 1999;116:479 492 EDITORIALS Helicobacter pylori, Acid, and Omeprazole Revisited: Bacterial Eradication and Rebound Hypersecretion See articles on pages 239 and 248. The interactions between
More informationIntragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic
Gut 1995; 37: 39-43 Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin 39 J Labenz, M Stolte, A L Blum,
More informationFor the convenience of storage, Cassette and Sample Tubes can be stored separately. OneStep. H.Pylori Antigen. RapiCard InstaTest.
CORTEZ DIAGNOSTICS, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 USA Tel: (818) 591-3030 Fax: (818) 591-8383 E-mail: onestep@rapidtest.com Web site: www.rapidtest.com See external label
More information헬리코박터제균요법에있어서 CYP2C19 유전형이판토프라졸과라베프라졸포함치료법에미치는영향. Introduction 울산대학교의과대학서울아산병원소화기내과
The Korean Journal of Helicobacter and Upper Gastrointestinal Research Vol. 8, No. 1, 15-19, July 2008 Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: Comparison between Pantoprazole
More informationClinical practice - breath tests
Clinical practice - breath tests G D Bell Gastroenterology Department, Sunderland District General Hospital, Sunderland, UK The underlying principle of the two non-invasive radio-labelled urea breath tests
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationOriginal article J Bas Res Med Sci 2015; 2(4):45-50.
Comparison between the effectiveness of Furazolidone and Clarithromycin on eradication of helicobacter pylori among patients with peptic ulcer Asghar Rahmani 1, Ali Jafari Haidarloo 2, Hoda Mabrokzadeh
More informationEradication therapy for peptic ulcer disease in Helicobacter pylori-positive people(review)
Cochrane Database of Systematic Reviews Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people(review) FordAC,GurusamyKS,DelaneyB,FormanD,MoayyediP FordAC,GurusamyKS,DelaneyB,FormanD,MoayyediP.
More informationEffect of Helicobacter pylori infection and its eradication on nutrition
Aliment Pharmacol Ther 2002; 16: 799 806. Effect of Helicobacter pylori infection and its eradication on nutrition T. FURUTA*, N. SHIRAI*, F. XIAO*, M. TAKASHIMA* & H. HANAI *First Department of Medicine
More informationBismuth subsalicylate in the treatment of H2 blocker
Gut, 1992, 33, 179-183 Departments of Gastroenterology and Hepatology and Clinical Microbiology, Medizinische Hochschule Hannover, Germany S Wagner M Gebel W Bar P Lange J Freise F W Schmidt Department
More informationTECHNOLOGY OVERVIEW: PHARMACEUTICALS
TECHNOLOGY OVERVIEW: PHARMACEUTICALS ISSUE 3.1 JUNE 1996 PHARMACEUTICAL MANAGEMENT OF PEPTIC ULCER DISEASE prepared by Ms. Christine Perras, BSc Phm Pharmaceutical Associate, CCOHTA and Dr. Nicolaas Otten,
More informationShort-Duration Furazolidone Therapy in Combination with Amoxicillin, Bismuth Subcitrate, and Omeprazole for Eradication of Helicobacter pylori
Original Article Short-Duration Furazolidone Therapy in Combination with Amoxicillin, Bismuth Subcitrate, and Omeprazole for Eradication of Helicobacter pylori Salman R. Hasan, Vahabzadeh Vahid 2, Pahlvanzadah
More informationAN ESTIMATED 30% to 40%
Helicobacter pylori Related Disease Guidelines for Testing and Treatment ORIGINAL INVESTIGATION Walter L. Peterson, MD; A. Mark Fendrick, MD; David R. Cave, MD, PhD; David A. Peura, MD; Susan M. Garabedian-Ruffalo,
More informationSequioa Education Systems, Inc. 1
Functional Diagnostic Medicine Training Program Module 2 The Functional Diagnostic Medicine Approach in the Treatment of Gastrointestinal Dysfunction and Disease Dr. Wayne L. Sodano, D.C., D.A.B.C.I. &
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1998, by the Massachusetts Medical Society VOLUME 339 D ECEMBER 24, 1998 NUMBER 26 SYMPTOMATIC BENEFIT FROM ERADICATING HELICOBACTER PYLORI INFECTION IN PATIENTS
More informationI. Kalfus MD, D. Riff MD, R. Fathi PhD, D. Graham MD
A Randomized Double Blind Placebo Controlled Phase III Study to Assess the Safety and Efficacy of Rifabutin Triple Therapy (RHB-105) for Helicobacter pylori (H. pylori) Infection in Dyspepsia Patients
More informationRapidity of diagnosis and management of H. Pylori in the endoscopy unit at Mater Dei Hospital
Rapidity of diagnosis and management of H. Pylori in the endoscopy unit at Mater Dei Hospital Abstract Introduction: H.pylori infection has been associated with various gastric pathologies and its prevalence
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationPharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W Record Status This is a critical abstract of an economic evaluation that
More informationSuccess Rate of Furazolidone Based Triple Therapy for Eradication of Helicobacter Pylori in Children
Original Article Iran J Pediatr Sep 2008; Vol 19 (No 3), Pp:244-248 Success Rate of Furazolidone Based Triple Therapy for Eradication of Helicobacter Pylori in Children Mehri Najafi, MD* 1 ; Ahmad Khodadad,
More informationGeneral practice. Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model.
Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model A E Duggan, K Tolley, C J Hawkey, R F A Logan Department of Public Health and Epidemiology,
More informationOriginal Policy Date
MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationEfficacy and Tolerability of a Third-Line, Levofloxacin-Based, 10-Day Sequential Therapy in Curing Resistant Helicobacter Pylori Infection
ORIGInAL PAPERs Efficacy and Tolerability of a Third-Line, Levofloxacin-Based, 10-Day Sequential Therapy in Curing Resistant Helicobacter Pylori Infection Antonio Tursi 1, Marcello Picchio 2, Walter Elisei
More informationHelicobacter pylori. Objectives. Upper Gastrointestinal Bleeding Peptic Ulcer Disease
Upper Gastrointestinal Bleeding Peptic Ulcer Disease Pharmacotherapy Issues in Acute Management and Secondary Prevention Peter J. Zed, B.Sc., B.Sc.(Pharm), Pharm.D. Pharmacotherapeutic Specialist - Emergency
More informationChapter 4. Helicobacter pylori eradication therapy analyses
Chapter 4 Helicobacter pylori eradication therapy analyses Chapter 4.1 Medley of Helicobacter pylori eradication regimens Combinations using lansoprazole Angela A.M.C. Claessens MD 1,2, Eibert R. Heerdink
More informationPharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole
Aliment Pharmacol Ther 2001; 15: 1563±1569. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole T. ANDERSSON*, K. ROÈ HSS, E.BREDBERG & M. HASSAN-ALIN *Clinical Pharmacology,
More informationOm epr azole, am ox icillin, clarithr omycin H elicobacter p y lori
: 58 6 2000 Om epr azole, am ox icillin, clarithr omycin H elicobacter p y lori, =A b s t r a c t s = T he e f f e ct of He lic obac te r p y lo ri eradic ation of triple therapy w ith ome prazole, am
More informationCommittee Approval Date: October 14, 2014 Next Review Date: October 2015
Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next
More informationH. pylori Antigen ELISA Kit
H. pylori Antigen ELISA Kit Catalog Number KA3142 96 assays Version: 04 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationAntral Atrophy, Helicobacter pylori Colonization, and Gastric ph
ANATOMIC PATHOLOGY Original Article Antral Atrophy, Helicobacter pylori Colonization, and Gastric ph BERNARDO RUIZ, MD, PELAYO CORREA, MD, ELIZABETH T.H. FONTHAM, DRPH, AND THIRUVENGADAM RAMAKRISHNAN,
More informationHelicobacter pylori is causally associated with gastritis, duodenal. A meta-analysis of the success rate of Helicobacter pylori therapy in Canada
ORIGINAL ARTICLE A meta-analysis of the success rate of Helicobacter pylori therapy in Canada Christopher Rodgers BSc, Sander Veldhuyzen van Zanten MD PhD C Rodgers, S Veldhuyzen van Zanten. A meta-analysis
More informationThe treatment of helicobacter pylori infection and its sequelae with emphasis on nitroimidazole resistance Wouden, Egbert-Jan van der
University of Groningen The treatment of helicobacter pylori infection and its sequelae with emphasis on nitroimidazole resistance Wouden, Egbert-Jan van der IMPORTANT NOTE: You are advised to consult
More informationThe life and death of Helicobacter pylori
S56 Gut 1998;43(suppl 1):S56 S60 The life and death of Helicobacter pylori UCLA and Wadsworth VA, Los Angeles, California, USA D Scott D Weeks G Sachs Byk Gulden, Konstanz K Melchers Correspondence to:
More informationACG Clinical Guideline: Treatment of Helicobacter pylori Infection
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division
More informationValue of Serology as a Noninvasive Method for Evaluating the Efficacy of Treatment of Helicobacter pylori Infection
1038 Value of Serology as a Noninvasive Method for Evaluating the Efficacy of Treatment of Helicobacter pylori Infection Guillermo I. Pérez-Pérez, Alan F. Cutler, and Martin J. Blaser From the Division
More informationCHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?
CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory
More informationomeprazole Changes in the intragastric distribution of Helicobacter pylori during treatment with PAPERS "C or 14C-urea breath test suggest that
12 Gut 1995; 36: 12-16 PAPERS Parkside Helicobacter Study Group, Central Middlesex and St Mary's Hospitals, London R P H Logan M M Walker J J Misiewicz P A Gummett Q N Karim J H Baron Correspondence to:
More informationCanadian Helicobacter pylori Consensus Conference
CONSENSUS CONFERENCE Canadian Helicobacter pylori Consensus Conference Richard Hunt MD, Alan BR Thomson MD PhD FRCPC FACG, Consensus Conference participants R Hunt, ABR Thomson, Consensus Conference participants.
More informationHelicobacter pylori:an Emerging Pathogen
Bacteriology at UW-Madison Bacteriology 330 Home Page Helicobacter pylori:an Emerging Pathogen by Karrie Holston, Department of Bacteriology University of Wisconsin-Madison Description of Helicobacter
More information